These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35947636)

  • 21. Effects of Ivacaftor in Three Pediatric Siblings With Cystic Fibrosis Carrying the Mutations G551D And F508del.
    Mainz JG; Arnold C; Hentschel J; Tabori H
    Arch Bronconeumol (Engl Ed); 2018 Apr; 54(4):232-234. PubMed ID: 29103672
    [No Abstract]   [Full Text] [Related]  

  • 22. Ivacaftor for patients with cystic fibrosis.
    Wainwright CE
    Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
    Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
    Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
    Burgener EB; Moss RB
    Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
    de Vries JM; Green D; Kucera JN; Fabbrini AL; Kidder M; Brown J; Wilsey M
    Pancreas; 2020 Jul; 49(6):e50-e51. PubMed ID: 32590622
    [No Abstract]   [Full Text] [Related]  

  • 28. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Future of Highly Effective Modulator Therapy in Cystic Fibrosis.
    Daines CL; Morgan WJ
    Am J Respir Crit Care Med; 2021 Jun; 203(12):1453-1455. PubMed ID: 33901406
    [No Abstract]   [Full Text] [Related]  

  • 30. Ivacaftor in a G551D homozygote with cystic fibrosis.
    Harrison MJ; Murphy DM; Plant BJ
    N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
    [No Abstract]   [Full Text] [Related]  

  • 31. CFTR Modulator Therapy for Cystic Fibrosis.
    Grasemann H
    N Engl J Med; 2017 Nov; 377(21):2085-2088. PubMed ID: 29099349
    [No Abstract]   [Full Text] [Related]  

  • 32. Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.
    O'Reilly R; Elphick HE
    Drug Des Devel Ther; 2013; 7():929-37. PubMed ID: 24039402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Promising new era dawns for cystic fibrosis treatment.
    Corbyn Z
    Lancet; 2012 Apr; 379(9825):1475-6. PubMed ID: 22530244
    [No Abstract]   [Full Text] [Related]  

  • 34. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
    Heltshe SL; Cogen J; Ramos KJ; Goss CH
    Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
    [No Abstract]   [Full Text] [Related]  

  • 35. Triple CFTR Modulator Therapy for Cystic Fibrosis.
    Holguin F
    N Engl J Med; 2018 Oct; 379(17):1671-1672. PubMed ID: 30334694
    [No Abstract]   [Full Text] [Related]  

  • 36. Remarkable progress toward new treatments for cystic fibrosis.
    Eldredge LC; Ramsey BW
    Lancet Respir Med; 2014 Dec; 2(12):962-4. PubMed ID: 25466347
    [No Abstract]   [Full Text] [Related]  

  • 37. Therapy for cystic fibrosis--the end of the beginning?
    Davis PB
    N Engl J Med; 2011 Nov; 365(18):1734-5. PubMed ID: 22047565
    [No Abstract]   [Full Text] [Related]  

  • 38. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update in Cystic Fibrosis 2014.
    Ong T; Ramsey BW
    Am J Respir Crit Care Med; 2015 Sep; 192(6):669-75. PubMed ID: 26371812
    [No Abstract]   [Full Text] [Related]  

  • 40. Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy.
    Lahiri T; Sullivan JS
    Pediatr Pulmonol; 2022 Feb; 57 Suppl 1():S60-S74. PubMed ID: 34473419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.